Vilon: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

Vilon is a synthetic dipeptide (Lys-Glu; KE), CAS 45234-02-4, belonging to the family of short peptide bioregulators described by the Khavinson group. In research models, its role as a modulator of thymic and immune activity and of gene expression has been explored. Compound intended solely for research use.

Vilon is one of the most studied dipeptides within the family of short peptide bioregulators developed and described by the group of Professor Vladimir Khavinson in St. Petersburg. It corresponds to the Lysine-Glutamic acid sequence (Lys-Glu), abbreviated as KE in single-letter code, with the molecular formula C11H21N3O5, a molecular weight of 275.31 g/mol, and CAS number 45234-02-4. Unlike long peptides or proteins, Vilon is an extremely small molecule —just two amino acids— which places it in the category of the "peptide bioregulators" originally conceived as simplified synthetic versions of peptide fractions obtained from animal tissues. Within this framework, Vilon was proposed as a synthetic analog associated with the activity of thymic preparations, within a line of work that sought short peptides capable of modulating immune functions and aging-related processes in experimental models.

From a structural standpoint, the simplicity of Vilon is one of its most notable characteristics. As a dipeptide with one basic residue (lysine) and one acidic residue (glutamic acid), it presents an amphoteric molecule of low molecular weight. The Khavinson group has advanced, in its body of work, the hypothesis that these short dipeptides and tripeptides can interact directly with DNA and with specific promoter regions, acting as signals capable of modulating gene transcription. It is important to emphasize that this mechanistic model comes largely from a single research group and from preclinical and in vitro work, so it must be treated as a research hypothesis and not as an independently established mechanism.

The proposed mechanism of action for Vilon is therefore framed within the idea of epigenetic regulation by short peptides. According to this line of work, dipeptides such as Lys-Glu could penetrate the cell and the nucleus, bind to specific DNA sequences or to histones, and modulate the expression of genes involved in cell proliferation, differentiation, and the immune response. In research models its possible influence on parameters of thymic function, on lymphocyte populations, and on markers associated with immunosenescence has been explored. Observations on cell proliferation and on the expression of certain genes in cultures have also been described in laboratory studies. However, the magnitude, independent reproducibility, and translational relevance of these findings remain subjects of debate, and there is no broad consensus outside the group that originated this research.

The documented research applications for Vilon are concentrated in areas related to experimental immunology and the biology of aging. It has been used as a tool in studies on the modulation of immune activity, particularly in contexts where the restoration or maintenance of thymic function in aged animal models is examined. Other lines of work have addressed its possible effect on hematological and immunological parameters, on the response to experimental insults, and on general indicators of vitality in experimental gerontology models. Within Khavinson's program, Vilon has frequently been studied alongside other bioregulators of the same series, comparing or combining effects between dipeptides and tripeptides directed at different tissues. These uses are strictly experimental and form part of a body of specialized literature that has not led to a broadly approved therapeutic use.

As for the level of evidence, scientific honesty requires being explicit: the available evidence on Vilon is limited and comes, for the most part, from a single research group and from preclinical, in vitro, and animal-model studies. Independent verification by outside laboratories is scarce, and the translation of the findings to rigorous, controlled clinical settings is very limited. For this reason, any claim about efficacy should be interpreted with caution and in the context of basic research. Vilon should not be considered a validated treatment or a product with approved therapeutic indications; its interest lies in its value as an experimental tool to explore the hypothesis of bioregulation by short peptides.

For the researcher, Vilon represents a paradigmatic example of the "peptide bioregulators" class: a very simple synthetic molecule, chemically well defined (Lys-Glu, CAS 45234-02-4), but whose biological profile rests on a body of evidence that is concentrated and not yet independently consolidated. Its handling in the laboratory requires the usual precautions for lyophilized peptides, and its use is justified only within the framework of research studies designed to better characterize its effects, its mechanism, and its reproducibility. In summary, it is a dipeptide of the Khavinson family with research applications documented in experimental immunology and gerontology, but with a level of evidence that must honestly be described as preliminary and limited.